Stereo-seq 를 통한 종에 구애받지 않는 전사체의 포괄적인 공간 프로파일링

Executive Industry Relevance

Stereo-seq enables comprehensive spatial transcriptomic profiling of both host and non-host RNA species in FFPE tissues, addressing a critical gap in unbiased, high-resolution mapping of cellular and microbial transcriptomes. This capability supports predictive confidence in target validation and biomarker discovery, particularly in complex tissue microenvironments such as tumors. The method's species-agnostic approach enhances portfolio decision-making by revealing intra- and inter-actome interactions relevant to therapeutic development.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Enables spatially resolved interrogation of transcriptomic heterogeneity within disease-relevant tissues.
• Supports identification of predictive and therapeutic biomarkers by mapping cell-type and pathogen interactions.
• Facilitates mechanistic de-risking through unbiased detection of coding and non-coding RNAs, including microbial and viral species.
• Improves predictive confidence for target selection in complex microenvironments.

Screening & Assay Development

• Prepares validated spatial transcriptomic maps for downstream functional screening workflows.
• Standardizes assay outputs with subcellular resolution and quantitative spatial data.
• Enables reproducible detection of diverse RNA species, supporting robust assay development.
• Provides high-content data for reliable compound evaluation in tissue context.

Translational & Preclinical Research

• Aligns spatial transcriptomic data with translational biomarker strategies in oncology and infectious disease models.
• Ensures continuity from discovery through preclinical validation by capturing host-pathogen and cell-cell interactions.
• Supports risk-adjusted advancement decisions by revealing tissue-specific transcriptomic signatures.
• Enhances predictive de-risking for late-stage biological risk assessment.

Pipeline & Workflow Integration

Stereo-seq integrates into the discovery-to-preclinical continuum by enabling spatially resolved, species-agnostic transcriptomic profiling from FFPE tissues, supporting both early discovery and translational research inflection points.

• Discovery Biology: Provides hypothesis testing and pathway clarification through unbiased RNA detection at subcellular resolution.
• Screening: Delivers quantitative, reproducible spatial transcriptomic outputs for assay readiness.
• Analytics: Generates high-content spatial data enabling comparative analysis of cell types and microbial loads.
• Translational Research: Connects spatial transcriptomic signatures to preclinical biomarker validation and disease modeling.
• Enterprise Reuse: Establishes a reusable platform for spatial profiling across diverse tissue types and disease models.

Operational & Enterprise Impact

• Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in target validation.
• Operational Value: Standardizes spatial transcriptomic workflows for reproducibility and scalability.
• Strategic Value: Enables informed go/no-go decisions and capital-efficient portfolio management.
• Portfolio Impact: Supports risk-adjusted prioritization and advancement of discovery programs.

Implementation Considerations

• Requires expertise in spatial transcriptomics and FFPE tissue handling.
• Demands advanced imaging, sequencing, and bioinformatics infrastructure.
• Necessitates cross-team standardization for sample preparation and data analysis.
• Adaptation may be needed for fatty or fragile tissues to ensure RNA accessibility and tissue adhesion.
• Careful contamination control is essential to distinguish true tissue signals from environmental artifacts.

Biopharma FAQs